Hemodiafiltration with endogenous reinfusion with and without acetate-free dialysis solutions: Effect on ESA requirement

P. G. Bolasco, P. M. Ghezzi, A. Serra, L. Corazza, S. Murtas, M. Mascia, M. Cossu, R. Ferrara, G. Cogoni, F. Cadinu, D. Casu, B. Contu, M. Passaghe, T. Ghisu, M. Ganadu, F. Logias

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Hemofiltrate reinfusion (HFR) is a form of hemodiafiltration (HDF) in which replacement fluid is constituted by ultrafiltrate from the patient 'regenerated' through a cartridge containing hydrophobic styrene resin. Bicarbonate-based dialysis solutions (DS) used in routine hemodialysis and HDF contain small quantities of acetate (3-5 mM) as a stabilizing agent, one of the major causes of intradialytic hypotension. Acetate-free (AF) DS have recently been made available, substituting acetate with hydrochloric acid. The impact of AF DS during HFR on Hb levels and erythropoietic-stimulating agent (ESA) requirement in chronic dialysis patients was assessed. Patients and Methods: After obtaining informed consent, 30 uremic patients treated by standard bicarbonate dialysis (BHD, DS with acetate) were randomized to treatment in 3-month cycles: first AF HFR, followed by HFR with acetate, and again AF HFR. At the beginning and end of each period, Hb and ESA requirements were evaluated. Results: A significant increase in the Hb level was observed throughout all periods of HFR versus BHD (from 11.1 to 11.86 g/dl; p = 0.04), with a significant decrease of ESA requirements from 29,500 to 25,033 IU/month (p = 0.04). Conclusion: Regardless of the presence or absence of acetate in DS, HFR per se allows a significant lowering of ESA dosage versus BHD, while at the same time increasing Hb levels. Taking for granted the clinical impact produced, HFR seems to provide a relevant decrease in end-stage renal disease patient costs.

Original languageEnglish
Pages (from-to)235-242
Number of pages8
JournalBlood Purification
Volume31
Issue number4
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Hemodiafiltration
Dialysis Solutions
Acetates
Bicarbonates
Dialysis
Cost of Illness
Styrene
Hydrochloric Acid
Excipients
Informed Consent
Hypotension
Chronic Kidney Failure
Renal Dialysis

Keywords

  • Acetate-free dialysis solutions
  • Anemia
  • Erythropoietic-stimulating agent
  • Hemodiafiltration with endogenous reinfusion
  • Hemofiltrate reinfusion

ASJC Scopus subject areas

  • Nephrology
  • Hematology

Cite this

Bolasco, P. G., Ghezzi, P. M., Serra, A., Corazza, L., Murtas, S., Mascia, M., ... Logias, F. (2011). Hemodiafiltration with endogenous reinfusion with and without acetate-free dialysis solutions: Effect on ESA requirement. Blood Purification, 31(4), 235-242. https://doi.org/10.1159/000322400

Hemodiafiltration with endogenous reinfusion with and without acetate-free dialysis solutions : Effect on ESA requirement. / Bolasco, P. G.; Ghezzi, P. M.; Serra, A.; Corazza, L.; Murtas, S.; Mascia, M.; Cossu, M.; Ferrara, R.; Cogoni, G.; Cadinu, F.; Casu, D.; Contu, B.; Passaghe, M.; Ghisu, T.; Ganadu, M.; Logias, F.

In: Blood Purification, Vol. 31, No. 4, 06.2011, p. 235-242.

Research output: Contribution to journalArticle

Bolasco, PG, Ghezzi, PM, Serra, A, Corazza, L, Murtas, S, Mascia, M, Cossu, M, Ferrara, R, Cogoni, G, Cadinu, F, Casu, D, Contu, B, Passaghe, M, Ghisu, T, Ganadu, M & Logias, F 2011, 'Hemodiafiltration with endogenous reinfusion with and without acetate-free dialysis solutions: Effect on ESA requirement', Blood Purification, vol. 31, no. 4, pp. 235-242. https://doi.org/10.1159/000322400
Bolasco, P. G. ; Ghezzi, P. M. ; Serra, A. ; Corazza, L. ; Murtas, S. ; Mascia, M. ; Cossu, M. ; Ferrara, R. ; Cogoni, G. ; Cadinu, F. ; Casu, D. ; Contu, B. ; Passaghe, M. ; Ghisu, T. ; Ganadu, M. ; Logias, F. / Hemodiafiltration with endogenous reinfusion with and without acetate-free dialysis solutions : Effect on ESA requirement. In: Blood Purification. 2011 ; Vol. 31, No. 4. pp. 235-242.
@article{5e0764376d8048db935d038d311050b1,
title = "Hemodiafiltration with endogenous reinfusion with and without acetate-free dialysis solutions: Effect on ESA requirement",
abstract = "Background: Hemofiltrate reinfusion (HFR) is a form of hemodiafiltration (HDF) in which replacement fluid is constituted by ultrafiltrate from the patient 'regenerated' through a cartridge containing hydrophobic styrene resin. Bicarbonate-based dialysis solutions (DS) used in routine hemodialysis and HDF contain small quantities of acetate (3-5 mM) as a stabilizing agent, one of the major causes of intradialytic hypotension. Acetate-free (AF) DS have recently been made available, substituting acetate with hydrochloric acid. The impact of AF DS during HFR on Hb levels and erythropoietic-stimulating agent (ESA) requirement in chronic dialysis patients was assessed. Patients and Methods: After obtaining informed consent, 30 uremic patients treated by standard bicarbonate dialysis (BHD, DS with acetate) were randomized to treatment in 3-month cycles: first AF HFR, followed by HFR with acetate, and again AF HFR. At the beginning and end of each period, Hb and ESA requirements were evaluated. Results: A significant increase in the Hb level was observed throughout all periods of HFR versus BHD (from 11.1 to 11.86 g/dl; p = 0.04), with a significant decrease of ESA requirements from 29,500 to 25,033 IU/month (p = 0.04). Conclusion: Regardless of the presence or absence of acetate in DS, HFR per se allows a significant lowering of ESA dosage versus BHD, while at the same time increasing Hb levels. Taking for granted the clinical impact produced, HFR seems to provide a relevant decrease in end-stage renal disease patient costs.",
keywords = "Acetate-free dialysis solutions, Anemia, Erythropoietic-stimulating agent, Hemodiafiltration with endogenous reinfusion, Hemofiltrate reinfusion",
author = "Bolasco, {P. G.} and Ghezzi, {P. M.} and A. Serra and L. Corazza and S. Murtas and M. Mascia and M. Cossu and R. Ferrara and G. Cogoni and F. Cadinu and D. Casu and B. Contu and M. Passaghe and T. Ghisu and M. Ganadu and F. Logias",
year = "2011",
month = "6",
doi = "10.1159/000322400",
language = "English",
volume = "31",
pages = "235--242",
journal = "Blood Purification",
issn = "0253-5068",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Hemodiafiltration with endogenous reinfusion with and without acetate-free dialysis solutions

T2 - Effect on ESA requirement

AU - Bolasco, P. G.

AU - Ghezzi, P. M.

AU - Serra, A.

AU - Corazza, L.

AU - Murtas, S.

AU - Mascia, M.

AU - Cossu, M.

AU - Ferrara, R.

AU - Cogoni, G.

AU - Cadinu, F.

AU - Casu, D.

AU - Contu, B.

AU - Passaghe, M.

AU - Ghisu, T.

AU - Ganadu, M.

AU - Logias, F.

PY - 2011/6

Y1 - 2011/6

N2 - Background: Hemofiltrate reinfusion (HFR) is a form of hemodiafiltration (HDF) in which replacement fluid is constituted by ultrafiltrate from the patient 'regenerated' through a cartridge containing hydrophobic styrene resin. Bicarbonate-based dialysis solutions (DS) used in routine hemodialysis and HDF contain small quantities of acetate (3-5 mM) as a stabilizing agent, one of the major causes of intradialytic hypotension. Acetate-free (AF) DS have recently been made available, substituting acetate with hydrochloric acid. The impact of AF DS during HFR on Hb levels and erythropoietic-stimulating agent (ESA) requirement in chronic dialysis patients was assessed. Patients and Methods: After obtaining informed consent, 30 uremic patients treated by standard bicarbonate dialysis (BHD, DS with acetate) were randomized to treatment in 3-month cycles: first AF HFR, followed by HFR with acetate, and again AF HFR. At the beginning and end of each period, Hb and ESA requirements were evaluated. Results: A significant increase in the Hb level was observed throughout all periods of HFR versus BHD (from 11.1 to 11.86 g/dl; p = 0.04), with a significant decrease of ESA requirements from 29,500 to 25,033 IU/month (p = 0.04). Conclusion: Regardless of the presence or absence of acetate in DS, HFR per se allows a significant lowering of ESA dosage versus BHD, while at the same time increasing Hb levels. Taking for granted the clinical impact produced, HFR seems to provide a relevant decrease in end-stage renal disease patient costs.

AB - Background: Hemofiltrate reinfusion (HFR) is a form of hemodiafiltration (HDF) in which replacement fluid is constituted by ultrafiltrate from the patient 'regenerated' through a cartridge containing hydrophobic styrene resin. Bicarbonate-based dialysis solutions (DS) used in routine hemodialysis and HDF contain small quantities of acetate (3-5 mM) as a stabilizing agent, one of the major causes of intradialytic hypotension. Acetate-free (AF) DS have recently been made available, substituting acetate with hydrochloric acid. The impact of AF DS during HFR on Hb levels and erythropoietic-stimulating agent (ESA) requirement in chronic dialysis patients was assessed. Patients and Methods: After obtaining informed consent, 30 uremic patients treated by standard bicarbonate dialysis (BHD, DS with acetate) were randomized to treatment in 3-month cycles: first AF HFR, followed by HFR with acetate, and again AF HFR. At the beginning and end of each period, Hb and ESA requirements were evaluated. Results: A significant increase in the Hb level was observed throughout all periods of HFR versus BHD (from 11.1 to 11.86 g/dl; p = 0.04), with a significant decrease of ESA requirements from 29,500 to 25,033 IU/month (p = 0.04). Conclusion: Regardless of the presence or absence of acetate in DS, HFR per se allows a significant lowering of ESA dosage versus BHD, while at the same time increasing Hb levels. Taking for granted the clinical impact produced, HFR seems to provide a relevant decrease in end-stage renal disease patient costs.

KW - Acetate-free dialysis solutions

KW - Anemia

KW - Erythropoietic-stimulating agent

KW - Hemodiafiltration with endogenous reinfusion

KW - Hemofiltrate reinfusion

UR - http://www.scopus.com/inward/record.url?scp=78651380974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651380974&partnerID=8YFLogxK

U2 - 10.1159/000322400

DO - 10.1159/000322400

M3 - Article

C2 - 21242676

AN - SCOPUS:78651380974

VL - 31

SP - 235

EP - 242

JO - Blood Purification

JF - Blood Purification

SN - 0253-5068

IS - 4

ER -